The high-stakes legal battle over a widely used abortion pill has left some blue states busily stockpiling the medication, in anticipation of a time when it could no longer be easily accessible.
The big picture: At least two states say they are creating reserves of mifepristone to continue enabling access to the two-pill regimen for medication abortion that’s at the center of the legal battle. Two others are focusing on the other pill, whose availability isn’t threatened, to offer an alternative.
- Medication abortion accounts for 54% of abortions in the U.S., and 98% of those used mifepristone, an abortion drug normally used alongside a second pill, misoprostol.
- Misoprostol can be used on its own to terminate a pregnancy, but the method is slightly less effective. The combination regimen is considered the gold standard by health providers.
Driving the news: Last week, the Supreme Court temporarily blocked lower court rulings that put restrictions on the use of mifepristone that the Food and Drug Administration had lifted over the years, including a ban on teleprescribing.
- Mifepristone is still available without those limitations until at least Wednesday while anti-abortion groups respond.
- But courts have yet to settle anti-abortion groups challenge to the FDA’s overall authorization, and the case could well wind up at the high court again.
What’s happening: The states that have said are stockpiling abortion pills have laws protecting abortion access.
- In California, Gov. Gavin Newsom (D) said the state “secured an emergency stockpile” of up to 2 million doses of misoprostol.
- MassachusettsGov. Maura Healey (D) requested the University of Massachusetts purchase around 15,000 doses of mifepristone and has directed individual health providers to do so as well, which the state says will “ensure sufficient coverage … for more than a year.”
- The state will financially support any provider by paying for the doses.
- New York Gov. Kathy Hochul (D) stockpiled 150,000 doses of misoprostol, a projected five-year supply, “to meet anticipated needs.”
- In Washington state, Gov. Jay Inslee (D) purchased a three-year supply of mifepristone through the state’s Department of Corrections, which has a pharmacy license.
- Dispensing mifepristone in Washington at the moment is also protected by a separate federal ruling that prohibits the FDA from rolling back access to the drug.
State of play: The Supreme Court could reinstate the restrictions or even scrap the FDA’s approval of the drug, which could cut off access in Massachusetts and Washington state.
- If the FDA’s authorization is revoked, it’s possible that providing mifepristone would violate the Food, Drug and Cosmetic Act “because that would cause the introduction of an unapproved drug into interstate commerce,” said Delia Deschaine, an attorney at Epstein Becker Green specializing in FDA regulatory matters.
- However, the Justice Department is responsible for enforcing federal law and has argued that mifepristone is safe and effective. That makes it unlikely that the federal government would enforce the law against providers or pharmacies that are prescribing or dispensing mifepristone, even if it’s technically unapproved, Deschaine added.
Yes, but: States would still be subject to the restrictions if they take effect after Wednesday, particularly the in-person prescribing and dispensing requirement.